04:32:35 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-17 Bokslutskommuniké 2024
2024-11-19 Kvartalsrapport 2024-Q3
2024-08-20 Kvartalsrapport 2024-Q2
2024-05-23 Ordinarie utdelning NEOD 0.00 SEK
2024-05-22 Årsstämma 2024
2024-05-07 Kvartalsrapport 2024-Q1
2024-02-16 Split NEOD 100:1
2024-02-16 Bokslutskommuniké 2023
2024-02-02 Extra Bolagsstämma 2024
2023-11-27 Kvartalsrapport 2023-Q3
2023-08-19 Kvartalsrapport 2023-Q2
2023-07-27 Extra Bolagsstämma 2023
2023-05-24 Ordinarie utdelning NEOD 0.00 SEK
2023-05-23 Årsstämma 2023
2023-05-11 Kvartalsrapport 2023-Q1
2023-02-17 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning NEOD 0.00 SEK
2022-05-19 Årsstämma 2022
2022-05-12 Kvartalsrapport 2022-Q1
2022-02-25 Extra Bolagsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-27 Ordinarie utdelning NEOD 0.00 SEK
2021-05-26 Kvartalsrapport 2021-Q1
2021-05-26 Årsstämma 2021
2021-02-17 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-11-19 Extra Bolagsstämma 2020
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-29 Ordinarie utdelning NEOD 0.00 SEK
2020-05-28 Årsstämma 2020
2020-05-26 Kvartalsrapport 2020-Q1
2020-02-05 Bokslutskommuniké 2019
2020-01-28 Extra Bolagsstämma 2019
2019-11-21 Kvartalsrapport 2019-Q3
2019-08-28 Kvartalsrapport 2019-Q2
2019-05-24 Ordinarie utdelning NEOD 0.00 SEK
2019-05-23 Årsstämma 2019
2019-05-21 Kvartalsrapport 2019-Q1
2019-02-21 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Neodynamics är verksamt inom medicinteknik. Idag är verksamheten inriktad mot att utveckla och kommersialisera produkter för behandling av kritiska sjukdomar. Via egenutvecklad mikropulsteknologi erbjuder bolaget precisionsbehandlingar mot bland annat cancer. Lösningarna används främst vid behandling avb bröstcancer hos kvinnor. Huvudkontoret ligger i Lidingö.
2023-11-13 14:00:00

The Board of Directors and Management Team has today decided to streamline its operations to maximize its return on investment in key launch regions.

As a result of these challenging but necessary changes to the organizational structure, dedicated team members will be impacted as the Company operates with a reduced headcount moving forward.

Current global financial market conditions dictate a more cost-effective approach to commercializing the NeoNavia system to clinicians in our target markets. A key component of this plan is to match staffing levels to current conditions, while still maintaining an appropriate presence that facilitates continued commercial efforts in these markets.

Meanwhile, the company continues to build strong advocacy and clinical use amongst physician customers in key centres. Initial orders for the full complement of our Pulsed Biopsy System are scheduled for delivery later this month and into early 2024.

“We’ve made the decision to reduce costs with due consideration to our current cash situation. We truly believe we are close to a commercial breakthrough, which has been validated by positive customer feedback and recent orders we’ve received. Therefore, we have decided to focus on balancing our continued commercialisation efforts, with the difficult trading conditions in the market.” says Anna Eriksrud, CEO.